Sodium-Glucose co-transporter 2 inhibitors (SGLT2i) are novel therapeutic agents used for the treatment of type 2 diabetes mellitus (T2DM) and have reno-protective effects in patients with T2DM with or without renal impairment [1]. One of the previous meta-analysis included only 3 trials which showed reduction in major adverse cardiac events by 11% [2]. There were new trials published showing beneficial effects of SGLT2 inhibitors after this meta-analysis. Therefore, we have performed a meta-analysis including those trials to analyze if beneficial effects of SGLT2i still persist.
